The purpose of the trial is to compare the effect of adding the new drug to usual treatment versus adding a placebo. Patients receive a combination of chemotherapy that may include irinotecan, oxaliplatin, paclitaxel albumin-bound, gemcitabine, fluorouracil, and calcium folinate hydrate. The oral study medication or the placebo is taken each day, while the chemotherapy drugs are given through an IV infusion on scheduled days.

Participants are randomly assigned to one of the two groups and neither they nor the doctors know which group they are in. Treatment cycles are repeated every few weeks, with regular visits for drug administration, blood tests, and imaging scans to check the tumor. The study continues until the disease progresses, side effects require stopping treatment, or a predefined period of follow‑up is completed.

Participants will receive a series of injections of either the study drug or the placebo over several months, with regular clinic visits for safety checks and simple breathing tests. One key breathing test measures the amount of air expelled in the first second of a forced breath, known as Forced Expiratory Volume in 1 second, to see how lung function changes. Throughout the study, people will complete questionnaires that assess health status and symptoms, such as the SGRQ-C (a quality‑of‑life survey), the CAAT (a symptom score), and the E-RS:COPD diary (records daily breathing problems). Researchers will also monitor for any side effects, using terms like TEAEs (any undesirable effects), AESIs (specific safety concerns), and SAEs (serious problems). Blood samples will be taken to check the drug level and to look for antidrug antibodies, which are the body’s immune response to the medication.

The purpose of the study is to assess how well Mirikizumab works in treating these diseases over an extended period. Participants in the study will receive the medication and be monitored to see how their symptoms change over time. The study will look at whether the medication helps achieve clinical remission, which means a significant reduction or disappearance of symptoms, in participants with either Ulcerative Colitis or Crohn’s Disease.

Throughout the study, participants will receive regular injections of Mirikizumab and will have follow-up visits to track their progress. The study aims to provide valuable information on the long-term use of Mirikizumab in young patients with these chronic conditions, helping to determine its potential benefits and any side effects that may occur during treatment.

The aim is to find out whether the nasal dose of the study drug reduces the pain measured by the Premature Infant Pain Profile‑Revised during the first 30 seconds after the eye speculum is placed. Infants are randomly assigned to receive either the study drug or the placebo, then undergo the standard eye screening while pain scores and basic vital signs are recorded. After the exam the infants continue to be observed for a short period to monitor any breathing changes, oxygen needs, crying, sleep, or other reactions before returning to regular care.

The primary aim is to evaluate how well this combination works in controlling the disease. Participants receive the injection and the capsule on a repeated schedule, typically every few weeks, and are followed for several months with regular doctor visits, blood tests, and imaging to check for disease activity and any side effects. The study continues until a predefined number of treatment cycles are completed or if a participant experiences significant toxicity that requires stopping the therapy.

The purpose of the study is to find out whether the medication can slow the narrowing of the valve and improve the ability to exercise. Participants are randomly assigned to receive either the study drug or the placebo for about a year, with regular clinic visits. During the study, doctors will use an echocardiogram (an ultrasound picture of the heart) to see how big the valve opening is, and a peak VO2 test, measured during a CPET (a breathing and heart test done while exercising), to check how well the body uses oxygen. A CT scan (a detailed X‑ray picture) will also be performed to look at calcium buildup in the valve. If the valve becomes too narrow, doctors may discuss procedures such as TAVR (a catheter‑based valve replacement) or SAVR (surgical valve replacement).

Throughout the trial, participants will be monitored for any side effects, and safety checks will be done at each visit. The study team will collect information about health changes and any additional treatments needed, while keeping participants’ personal information confidential.

Participants in the study will be randomly assigned to receive either atorvastatin or a placebo, which is a tablet that looks like the medication but does not contain the active ingredient. The study will compare the effects of two different doses of atorvastatin, 20 mg and 40 mg, to see if they can decrease the frequency of migraines. The trial will last for several weeks, during which participants will take the medication daily and report the number of migraine days they experience.

The purpose of this study is to confirm whether the positive effects of atorvastatin observed in smaller studies can be replicated in a larger group of people. By participating, individuals will help researchers understand if atorvastatin can be an effective preventative treatment for those suffering from episodic migraines. The study is designed to be thorough and will involve multiple centers to ensure a comprehensive evaluation of the medication’s effects.

Participants are randomly assigned to either the active drug or placebo and will take the tablets daily for roughly 18 months alongside their cancer treatment. Heart function is measured at the start and at the end of the study using CMR, a special type of MRI that visualizes the heart. The primary assessment is the change in LVEF, which indicates how well the left side of the heart pumps blood. Additional evaluations include GLS, a measure of how the heart muscle stretches during beats, and blood tests for NT-proBNP and the high‑sensitivity cardiac injury markers hs‑TnI and hs‑TnT.

The study uses a step-by-step treatment plan. Each person will have periods with atorvastatin, periods with placebo, and a period with no study treatment. The order of these periods is arranged by chance. During the study, muscle symptoms are checked over time to compare how they change during each period.

The study is designed to help understand statin-associated muscle symptoms, which are muscle problems that some people notice while taking statin medicines such as atorvastatin. It also looks at whether some symptoms may be nocebo or misattributed, meaning they are felt as real symptoms but may not be caused by the medicine itself.

The purpose of the study is to determine if niraparib can help patients live longer without the disease getting worse, compared to temozolomide. Participants in the study will be randomly assigned to receive either niraparib or temozolomide. The study will monitor the participants over time to see how the treatments affect their health and the progression of their glioblastoma.

Throughout the study, researchers will also look at how the treatments impact overall survival, which means the length of time patients live after starting the treatment. Additionally, the study will assess the participants’ symptoms, quality of life, and any side effects they may experience. This information will help determine the safety and effectiveness of niraparib compared to temozolomide for treating this specific type of glioblastoma.

Participants are assigned to one of the study treatments and receive injections over time during regular study visits. The study team follows how the cancer responds and watches for side effects and other health changes. It also looks at how long the treatment effects last and how the treatments affect daily well-being and symptoms.

People in the study are placed into one of the treatment groups by chance. Treatment is given as intravenous infusion, which means medicine is delivered slowly through a vein. The study is planned to follow people over time while they receive treatment and after treatment ends to see how they do. The trial also watches for side effects, including cytokine release syndrome, a strong immune reaction, and ICANS, which is a group of brain and nerve symptoms that can happen with some immune treatments.

Obrixtamig is also known by the code name BI 764532. It is a type of treatment called a T cell engager, which is designed to help the immune system find and attack cancer cells that have DLL3 on their surface. The study is for previously untreated cancer that is DLL3-positive, meaning the cancer cells have this marker.

In the study, people are randomly assigned to receive either the new treatment combination or the standard treatment combination. The medicines are given as intravenous infusion, which means they are delivered slowly through a vein. Treatment is given in cycles over time, with regular visits for infusions and checks by the study team. The study will look at how long people live and will also follow symptoms and side effects, including breathing problems, chest pain, cough, and treatment-related reactions such as CRS and ICANS. CRS, or cytokine release syndrome, is a strong immune reaction that can cause fever and other symptoms. ICANS, or immune effector cell-associated neurotoxicity syndrome, is a brain and nerve problem that can affect thinking, speech, or alertness.

The purpose of the study is to explore whether this approach can improve insulin absorption and manage blood sugar levels more effectively. Participants will receive either the glucagon treatment or a placebo, and the study will monitor how their blood sugar levels respond over a short period. The treatment is administered subcutaneously, meaning it is injected just under the skin.

Throughout the study, various measurements will be taken to understand how the body processes insulin and glucagon. These include monitoring blood sugar levels and using special cameras and devices to assess how well the treatment is working. The study is expected to continue until the end of 2024, providing valuable insights into managing type 1 diabetes more effectively.

During the study, participants will receive treatment for up to 12 months. The researchers will measure several things to see if the treatment is helping, including changes in body weight and appetite over a 12-week period. Body weight will be tracked from the beginning of the study, and appetite will be measured using a questionnaire that asks specific questions about eating and food-related concerns. The study will also look at muscle mass using imaging scans such as CT or MRI, which are types of medical imaging that create detailed pictures of the inside of the body. Physical function will be tested through simple exercises like a chair stand test, and daily physical activity levels will be monitored.

Throughout the study, doctors will carefully monitor participants for any side effects or unwanted reactions to the treatment. Participants will also complete questionnaires about their quality of life, how severe their symptoms are, and whether they notice any changes in their condition. Blood samples will be taken to measure the levels of the medication in the body. The study will track overall health outcomes and how the cancer responds to ongoing treatment during this time.

The purpose of this study is to examine how well long-term maintenance treatment with ketamine works for keeping depression symptoms from coming back after an initial treatment period. The study is designed to compare different treatment approaches over time to see which one is most effective at preventing depression from returning. Participants will be divided into three different treatment groups to compare the results. The study will look at how long it takes for depression symptoms to come back after the initial treatment phase and after the last ketamine infusion, using a depression rating scale to measure symptom severity.

During the study, participants will receive ketamine infusions according to their assigned treatment group, with the treatment lasting up to 10 days in total. The maximum daily dose will be 150 milligrams, and the maximum total dose across all infusions will be 2700 milligrams. Throughout the study, doctors will monitor participants for any unwanted effects or reactions to the treatment through interviews, observations, questionnaires, and review of medical records. Women who could become pregnant must have a negative pregnancy test before starting the study and before each maintenance ketamine infusion, and must use highly effective birth control methods throughout their participation in the study.

The study is designed as a crossover trial, which means that participants will receive both the active medication and placebo at different times, with periods in between where no study medication is given to wash out the previous treatment. The study begins with a two-week period where participants keep track of their headache attacks in a diary before starting any treatment. Then participants will go through two four-week treatment periods where they take either candesartan or placebo, with the order being randomly assigned. Between these treatment periods there is a wash-out phase. After completing these phases, there is an optional open treatment period where participants may continue with candesartan.

Throughout the study, participants will record their headache attacks, including how severe they are and how often they occur. The study will measure changes in the number of severe and very severe attacks per week, how many people experience at least a 50 percent reduction in attacks, and changes in headache intensity. Other measurements include how much rescue medication participants need to use, improvements in quality of life and disability related to cluster headaches, and overall impression of improvement. The study will also monitor for any side effects and changes in mood or suicidal thoughts using specific questionnaires.

The purpose is to determine if using both medications together works better than empagliflozin alone in preventing serious heart-related health issues in people with these three conditions. The study will particularly look at how well this combination prevents death from heart problems and reduces the need for hospital visits due to heart failure.

Participants in this study will receive treatment for about 51 months. During this time, they will take either the combination of both medicines or empagliflozin with a placebo. Their blood pressure, kidney function, and heart health will be monitored throughout the study period. The medications being tested are designed to help manage blood sugar levels and blood pressure while protecting the heart and blood vessels.

The purpose of this research is to determine if mezagitamab can reduce the amount of protein in the urine of people with Primary IgA Nephropathy. During the study, participants will receive either mezagitamab or placebo injections for up to 104 weeks (2 years). The medication or placebo will be given alongside their usual kidney disease treatments.

The study will monitor changes in kidney function and the amount of protein in participants’ urine throughout the treatment period. Researchers will also check for signs of improvement in other symptoms related to kidney disease, including the presence of blood in the urine. The study will track how well participants’ bodies respond to the treatment and measure the amount of medication in their blood.

The purpose of this study is to find out if adding bleximenib to the standard intensive chemotherapy treatment can help patients live longer without their disease getting worse compared to receiving standard chemotherapy with placebo. The standard treatment includes chemotherapy to put the disease into remission, followed by additional chemotherapy to strengthen this response, and then maintenance therapy to help keep the disease under control.

During the study, patients will receive either bleximenib or placebo together with their regular intensive chemotherapy treatment. The study follows patients through the initial treatment phase aimed at achieving remission, a consolidation phase to reinforce the response, and then a maintenance phase. Neither the patients nor their doctors will know whether they are receiving bleximenib or placebo during the study. The study will monitor how well the treatment works and track patient outcomes over time.

The purpose of this study is to find out which treatment combinations work best for children whose leukemia has returned. The study will compare different treatment approaches to see which ones help patients live longer without the disease coming back and which ones are safer with fewer side effects. For some patients, the study will test whether newer medications like inotuzumab ozogamicin or blinatumomab work better than standard chemotherapy treatments. For other patients, the study will look at whether using fewer chemotherapy courses before giving blinatumomab is just as effective as using more chemotherapy courses.

During the study, patients will receive treatment in different phases. The first phase aims to reduce the cancer cells in the body, and this is called induction therapy. After this, patients may receive additional treatment phases called consolidation therapy to help keep the cancer from coming back. Throughout treatment, doctors will check how much disease remains in the body using special tests that can detect very small amounts of cancer cells. Based on these test results and other factors, doctors will decide which specific treatment plan is best for each patient. Some patients may eventually receive a stem cell transplant as part of their treatment plan.

The purpose of this study is to measure how well this treatment combination works over a three-year period and to examine its safety in children, adolescents, and young adults with these types of leukemia. The treatment approach uses a modified chemotherapy plan that includes three cycles of blinatumomab without traditional consolidation chemotherapy, combined with continuous use of the targeted drugs. The study will track various side effects including infections, mouth sores, nerve problems, cytokine release syndrome which is a reaction from the immune system, low levels of protective antibodies in the blood, treatment delays, and deaths related to treatment.

During the study, patients will receive a combination of standard chemotherapy drugs including vincristine, steroids, and pegaspargase or calaspargase pegol, with or without an anthracycline drug. The treatment plan is designed to work differently for the two types of leukemia, with patients having already started some initial therapy before joining the study. The study will follow patients to see how many remain free from disease events over three years and will also track overall survival rates and how the treatment works based on the specific genetic changes present in each patient’s leukemia.

The study involves several phases that participants will go through over time. First, there is a one-week period before treatment starts where participants keep a diary of their headache attacks to establish a starting point. Then comes a three-week blinded phase where participants take either candesartan up to 32 milligrams daily or placebo, with neither the participants nor the doctors knowing which treatment is being given. During this time, participants continue to record their headache attacks, how severe they are, and what medications they use to treat them. After the three-week blinded phase, there is an optional treatment period where participants may continue taking the study medication, followed by a wash-out phase where the medication is stopped to see what happens.

Throughout the study, participants will be asked to complete questionnaires about how much their condition has improved, how the headaches affect their daily life, and how they are feeling emotionally. The study will track how often severe and very severe attacks occur, how intense the attacks are, and how much rescue medication participants need to use. Researchers will also monitor how long it takes for attacks to stop completely and whether attacks return after treatment ends. The study is designed to gather information about whether candesartan can effectively prevent cluster headache attacks and improve the quality of life for people living with this condition.

The main purpose of this research is to determine the safest and most effective dose of mezigdomide when used together with elranatamab, and to understand how well this combination works in treating the disease. The study will look at how participants respond to the treatment and monitor any side effects that may occur.

During the study, participants will receive the combination treatment and undergo regular medical check-ups. Doctors will track how well the treatment is working by measuring the amount of cancer in the body and monitoring the participants’ overall health. They will also look at how long the treatment keeps working and how it affects participants’ survival.

The purpose of this research is to determine how effective the combination of glofitamab and pirtobrutinib is in treating patients with Mantle Cell Lymphoma, both in those who have previously received treatment and in those who have never been treated before. The study includes two groups of patients: those whose disease has returned or worsened after previous treatments, and elderly patients who have not yet received any treatment for their condition.

During the study, patients will receive treatment for up to 36 months. The treatment involves regular doses of medication according to a specific schedule. Patients will be monitored throughout the study period to assess how well the treatment is working and to check for any side effects. The study team will track whether the cancer improves, stays the same, or gets worse over time.

The purpose of this study is to determine if using a combination of narrow-spectrum antibiotics with gentamicin is as safe and effective as using broad-spectrum antibiotics alone in treating community-acquired sepsis. All medications in the study are given through an intravenous route, which means they are administered directly into the vein.

Participants in the study will receive one of these treatment approaches for up to three days. During and after treatment, doctors will monitor patients’ health status, including how well their kidneys are working and their overall recovery. The study will track various aspects of patient recovery, including time spent in the hospital and need for additional treatments.

Multiple Myeloma is a type of blood cancer that affects plasma cells, which are special white blood cells that help fight infections. The study aims to determine which treatment combination is more effective at eliminating cancer cells to a level that cannot be detected by very sensitive testing methods.

The medications used in this study are given in different ways. Lenalidomide is taken by mouth in capsule form, while Daratumumab and Linvoseltamab are given through an infusion into a vein. Dexamethasone can be given either as tablets by mouth or as an injection. The treatment continues for several weeks, and patients will need regular visits to the hospital for monitoring and receiving their medications.

The purpose of this research is to determine if cagrilintide is more effective than placebo in helping people lose weight. The study will specifically look at whether the medication can help people achieve a reduction of at least 5% of their body weight. During the study, participants will receive either cagrilintide or placebo injections for approximately 64 weeks.

The study will measure various health indicators including changes in body weight, waist size, blood pressure, and different types of cholesterol in the blood. It will also assess how the treatment affects quality of life and overall health. Throughout the study, participants’ safety will be monitored by tracking any side effects that may occur.

The purpose of this study is to determine how well AZD0780 works compared to placebo in lowering LDL cholesterol levels in patients who already take other cholesterol-lowering medications. The study will last for 52 weeks, during which participants will receive either AZD0780 or placebo in addition to their usual cholesterol-lowering treatments.

Throughout the study, researchers will monitor changes in various types of cholesterol and related substances in the blood, including apolipoprotein B, non-HDL cholesterol, total cholesterol, and lipoprotein(a). The main focus will be on measuring how much the LDL cholesterol levels change after 12 weeks of treatment.

The treatment involves two medications: TECVAYLI (teclistamab), which is given as an injection under the skin, and KIOVIG, which is given through an intravenous infusion. TECVAYLI is a specialized antibody that helps the immune system fight cancer cells, while KIOVIG contains antibodies that help prevent infections in patients whose immune systems are weakened by cancer treatment.

During the study, patients will receive their regular cancer treatment with TECVAYLI and will be divided into two groups. One group will receive KIOVIG preventively from the start of their cancer treatment, while the other group will only receive KIOVIG if they develop infections. The study will track how well these different approaches work in preventing serious infections over a period of 12 months.

The purpose of the study is to assess how safe and well-tolerated Pirtobrutinib is in people with ITP and to determine the appropriate doses for further research. The study is divided into two phases. In the first phase, participants will receive different doses of Pirtobrutinib to find the safest and most effective dose. In the second phase, the effectiveness of Pirtobrutinib will be compared to a placebo to see if it helps improve platelet counts in participants.

Participants in the study will take the medication orally and will have regular visits to monitor their health and platelet levels. The study aims to see if Pirtobrutinib can help maintain stable platelet counts without the need for additional treatments. The trial will continue until 2027, with the recruitment of participants expected to start in 2025. This research is important for finding new ways to manage and treat ITP effectively.

The purpose of the study is to see if ferric derisomaltose can help reduce the number of deaths related to heart problems and the number of times patients need to be hospitalized due to worsening heart failure. Participants in the study will be randomly assigned to receive either the iron treatment or no iron treatment. The study will monitor participants over a period of time to track their health outcomes, such as hospital visits and overall survival.

Throughout the study, researchers will collect information on various health indicators, including changes in heart failure symptoms and iron levels in the blood. The study aims to provide valuable insights into whether treating iron deficiency with ferric derisomaltose can improve the health and quality of life for people with Chronic Heart Failure.

The purpose of the study is to see if children with a chronic wet cough improve more when they take Augmentin for 14 days compared to those who take a placebo. Additionally, the study will explore whether extending the treatment to 28 days affects the time it takes for the cough to return. The study will also look at how the bacteria in the airways and gut, as well as inflammation and genetics, might influence the cough and its treatment.

Participants in the study will receive either the medication or the placebo for a set period. Researchers will monitor the children’s symptoms and any changes in their cough. The study will also examine the presence of bacteria and viruses, the diversity of bacteria in the airways and gut, and markers of inflammation in the body. The goal is to understand how these factors relate to the cough and its treatment, and to assess the overall quality of life for the children involved.

In this study, two medications are being used. The first is Plavix, which contains the active ingredient clopidogrel and is taken as a film-coated tablet. The second is Fragmin, which contains dalteparin sodium and is given as an injection. The purpose of the study is to see if adding antiplatelet therapy to the usual treatment can more effectively prevent blood clots in patients with pancreatic cancer.

Participants in the study will receive either the standard treatment alone or the standard treatment plus the antiplatelet therapy. The study will last for up to 12 months, during which time the safety and effectiveness of the treatments will be monitored. The goal is to determine if the combination of treatments can reduce the risk of blood clots without causing significant side effects, such as major bleeding.

Participants in the study will receive the treatment through a method called intravenous infusion, which means the plasma is given directly into the bloodstream through a vein. The study will last for about one year, during which the health and well-being of the participants will be closely monitored. The main goal is to observe any side effects and to ensure that the treatment is feasible for patients to undergo.

In addition to monitoring safety, the study will also look at changes in cognitive abilities, which are mental processes like memory and thinking. This will be done using various tests, such as the Mini-Mental State Examination (MMSE) and other cognitive assessments. The results will help determine if the plasma transfusion has any impact on the progression of Alzheimer’s disease symptoms. The study is expected to continue until 2030, providing valuable insights into this potential treatment option.